Chunumunu
Kyverna Therapeutics (KYTX), which is developing therapies for autoimmune disorders such as lupus and multiple sclerosis, has filed a $100 million initial public offering proposal.
Kyverna did not specify any terms in its filing with the SECbut he indicated that he was looking to raise $100 million, a figure that is likely a placeholder and subject to change.
The Emeryville, California-based biotechnology company hopes to list its shares on Nasdaq under the symbol KYTX. Underwriters include JP Morgan, Morgan Stanley, Leerink Partners and Wells Fargo Securities.
Kyverna's lead program, KYV-101, is a CD19 CAR T-cell therapy licensed by the National Institutes of Health. The product is in Phase 1 testing for lupus nephritis and systemic sclerosis, and in Phase 2 testing for myasthenia gravis and multiple sclerosis.
